Research programme: CD26 antigen antagonists - Biovitrum

Drug Profile

Research programme: CD26 antigen antagonists - Biovitrum

Alternative Names: SNT 189546

Latest Information Update: 24 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Santhera Pharmaceuticals
  • Developer Swedish Orphan Biovitrum
  • Class
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum
  • 12 Mar 2008 This programme is still in preclinical development
  • 17 Aug 2005 Santhera Pharmaceuticals and Biovitrum AB have entered into an agreement that gives Biovitrum exclusive worldwide rights to develop and commercialise compounds from Santhera's DDP IV inhibitor programme for a range of metabolic diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top